15 results about "Glycyrrhetin" patented technology

The invention discloses liquiritigenin and isoliquiritigenin produced by directionally converting liquiritin and isoliquiritigenin through lactobacillus plantarum CCFM1275 and application of the liquiritigenin and the isoliquiritigenin. Researches show that the lactobacillus plantarum CCFM1275 can grow in a fermentation base material rich in a licorice extract, and liquiritin and isoliquiritin in licorice can be converted into liquiritigenin and isoliquiritigenin respectively, so that utilization of active ingredients of liquiritin and isoliquiritigenin by an organism is facilitated, and the effect of the licorice extract is improved. Compared with the licorice root extract, the fermented licorice root postbiotics obtained by fermenting and converting the licorice root extract through the lactobacillus plantarum CCFM1275 can further improve the effects of the licorice root extract in the aspects of reducing liver lipid accumulation, lowering lipid and resisting aging, can be used for preparing products with the effects of preventing and / or treating fatty liver and obesity and / or resisting aging, and has a huge application prospect.

The invention provides a compound feed additive for relieving stress response of marine fishes, which is prepared by the following steps: mixing raw materials such as hermetia illucens protein and the like to prepare a premix, and embedding the premix by using a lac-glycyrrhizic acid system to prepare lac microcapsules; then modifying the fucoidin by adopting glycyrrhizin and gamma-linolenic acid, embedding rhodosporidium palustris and bacillus pumilus by using the fucoidin to prepare compound bacterium nano-particles, and finally mixing the lac microcapsules and the compound bacterium nano-particles in proportion. According to the invention, excessive secretion of cortisol of marine fish can be effectively inhibited, hermetia illucens protein provides rich nutrition and reduces muscle decomposition, and compound microorganisms are beneficial to maintaining intestinal microecological balance and improving the utilization rate of nutrition. The prepared compound feed additive can be directly splashed into a culture or transportation water body or added into a feed, so that the stress reaction of the marine fish is effectively relieved, the survival rate of the marine fish is increased, and powerful support is provided for culture of the marine fish.

Composition, in particular pharmaceutical composition, in the form of a fixed dosage (solid dosage form) for sucking and / or chewing, preferably for sucking, in particular lozenge, preferably for use in the prophylactic and / or therapeutic topical (local) treatment of inflammatory diseases of the mouth and throat, wherein the composition contains an effective, in particular pharmaceutically and / or therapeutically effective, amount of an active ingredient preferably suitable and / or effective for the topical (local) treatment of inflammatory diseases of the mouth and throat, in particular with antiseptic and / or antimicrobial properties, preferably with antibacterial and / or antiviral and / or antifungal properties, wherein the active ingredient is incorporated and / or embedded in a solid matrix, wherein the composition, in particular the solid dosage form and / or the matrix, releases the active ingredient upon topical (local) application and / or use, preferably by sucking and / or chewing, preferably by sucking, in the oral and pharyngeal cavity; wherein the active ingredient is octenidine, in particular in the form of a pharmaceutically compatible and / or physiologically acceptable salt or ester, preferably in the form of a pharmaceutically compatible and / or physiologically acceptable salt, particularly preferably octenidine dihydrochloride; and wherein the composition, in particular the solid dosage form and / or the matrix, furthermore and / or additionally contains at least one further ingredient (a) and / or (b), in particular (a) and (b), wherein the at least one further ingredient (a) and / or (b) is selected from the group of (a) Flavor modulators, in particular selected from the group of the following components (i), (ii) and / or (iii): (i) Bitter (taste) masking agents, in particular selected from the group consisting of bitter taste receptor antagonists, preferably 4-(2,2,3-trimethylcyclopentyl)butanoic acid, and saponins, preferably glycyrrhizic acid (glycyrrhizin) and its salts or esters and / or glycyrrhetinic acid (glycyrrhetin) and its salts or esters, complexing agents, in particular cyclodextrins, and combinations or mixtures thereof, (ii) Bitter substances, in particular coffee extract and / or tea extract and / or their respective bitter substances, preferably coffee extract and / or its bitter substances, (iii) preferably natural or nature-identical (aroma) oils and / or essential oils, in particular with antiseptic and / or antimicrobial properties, preferably with antibacterial, antifungal and / or antiviral properties, in particular selected from the group of anise oils, in particular star anise oil, peppermint oil, eucalyptus oil, lavender oil, tea tree oil, chamomile oil, clove oil, rosemary oil, caraway oil, cinnamon oil, sage oil and fennel oil, as well as combinations or mixtures thereof; in particular wherein the ingredient (a) and / or the flavor modulator comprises a combination of at least two different components (i), (ii) and / or (iii), preferably a combination of components (i), (ii) and (iii); (b) Acidulants, in particular saliva-stimulating and / or flavor-enhancing acidulants, preferably acidulants authorized under pharmaceutical and / or food law and / or acidulants authorized as pharmaceutical additives and / or food additives, in particular selected from the group of tartaric acid and its salts, in particular sodium tartrate, sodium potassium tartrate (Rochelle salt) and calcium tartrate, citric acid and its salts, metatartaric acid, fumaric acid, ascorbic acid, phosphoric acid and its salts, stannous chloride, in particular tin(II) chloride, malic acid, lactic acid, adipic acid, succinic acid and other pharmaceutically compatible and / or physiologically acceptable organic acids and their salts, as well as their combinations or mixtures.

The present application relates to the technical field of traditional Chinese medicine extraction and separation, and particularly relates to a method for extracting glycyrrhizin from glycyrrhizin crude product and an extract containing glycyrrhizin prepared by the method. The method comprises the following steps: mixing solvents, adjusting pH value, controlling difference in solvent polarity of an extraction system, controlling extraction temperature, layering, vacuum concentration and spray drying to obtain glycyrrhizin finished product. The present application realizes efficient extraction and enrichment of glycyrrhizin by using purified water, ethyl acetate and n-heptane to form a composite extraction system based on the difference in solvent polarity.

The invention discloses a method for simultaneously detecting neotame and glycyrrhizin in tipping paper, which comprises the following steps: (1) sample extraction: weighing the cut tipping paper, adding into an acetonitrile aqueous solution, and carrying out ultrasonic extraction for a period of time to obtain an extracting solution; (2) sample dilution: diluting the extracting solution with a mixed solution of dihydric phosphate, acetonitrile and water, and filtering to obtain a test sample; and (3) sample determination: detecting by adopting a high performance liquid chromatography to obtain the content of neotame and glycyrrhizin in the tipping paper. According to the method disclosed by the invention, the neotame and the glycyrrhizin in the tipping paper can be fully extracted at one time, the chromatographic peak is good, and the detection time is short.

The invention discloses a rapid detection method of an exogenous sweetener in glycyrrhizin, which comprises the following steps: (1) weighing a certain amount of glycyrrhizin, adding an internal standard substance and pure water, carrying out ultrasonic extraction, and filtering to obtain a test sample; and (2) determining the exogenous sweetening agent in the standard solution and the test sample solution by adopting ultra-high performance liquid chromatography-tandem mass spectrometry. According to the method disclosed by the invention, chromatographic separation conditions, solvent components and detection conditions are optimized, and the eight exogenous sweeteners in glycyrrhizin are rapidly and simultaneously analyzed and detected by improving the component separation degree and the chromatographic peak shape and improving the mass spectrum response.

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

The invention discloses Pickering emulsion gel based on medicine-adjuvant integration and a preparation method and application thereof.The preparation method comprises the steps that ethylene glycol chitosan is added into a whey protein solution and stirred to be uniform, then glycyrrhizic aldehyde is added, stirring and mixing are conducted, and a whey protein-ethylene glycol chitosan-glycyrrhizic aldehyde composite solution is obtained; mixing the gastrodia elata volatile oil with clove oil, and performing ultrasonic homogenization to obtain an oil phase; adding the oil phase into a whey protein-ethylene glycol chitosan-glycyrrhizic aldehyde composite solution, carrying out high-speed shearing emulsification to obtain an emulsion, then refrigerating the emulsion, and inducing whey protein to denature and gelatinize to form the Pickering emulsion gel. Based on the idea of integration of medicines and auxiliary materials, the whey protein is used as a particle stabilizer, the main medicinal components of gastrodia elata volatile oil and clove oil are used as a mixed oil phase, the dosage of the auxiliary materials is reduced, and through screening of an emulsion gel aqueous phase, the prepared Pickering emulsion is compact in gel texture and high in stability, has a slow release effect on the medicinal components, and can be used for preparing the medicinal composition. The long-acting sleep improvement effect can be realized.

The application discloses a compound for preventing and treating alopecia and application thereof, and belongs to the technical field of biotechnology. The compound comprises oleuropein, glycyrrhetin and neored gospermidin in a weight ratio of (1-32):(4-8):(4-8). The application also discloses application of the compound in preparation of a product for preventing and / or treating alopecia. It is found that the compound of glycyrrhetin and neored gospermidin and oleuropein can enhance the pharmacological effect of oleuropein in promoting the proliferation of human hair papilla (DP) cells, inhibiting the expression of AR, improving the cell cycle of hair follicles, stimulating the Wnt10b / beta-catenin signal pathway, and up-regulating the expression of growth factors IGF-1, KGF and VEGF genes in skin tissues to promote hair growth, and can completely replace traditional western medicine and be used for preventing and treating androgenic alopecia.

The present disclosure provides a food composition for use in a method for treating and / or preventing and / or reducing the severity and / or reducing the relapse of otitis externa in a companion animal in need thereof, wherein the said food composition includes, as the sole active agents, glycyrrhizin and curcuminoid.

The invention belongs to the technical field of biological pharmacy, and provides application of glycyrrhizin in preparation of a medicine for treating white matter injury. Animal experiment results show that the HMGB1 inhibitor Gly can obviously improve rat WMI pathological changes, reduce rat brain white matter region HMGB1 expression, obviously reduce the number of rat brain white matter region NG2 + Olig2 + double positive cells and improve rat WMI afterbrain white matter region OLs differentiation disorder; the myelination disorder of the white matter region of the rat after WMI can be improved, and the number of myelination axons of the rat is obviously increased; and the learning ability and the spatial memory ability of the rats are improved. It is clear that Gly can inhibit expression of HMGB1, and an effective technical means is provided for treatment of white matter damage.

The invention relates to a buffered aqueous composition comprising fluticasone propionate dissolved therein in a concentration of at least 20 µg / mL, wherein the composition further comprises a saponin component selected from the group consisting of escin, glycyrrhizin, and Quillaja saponaria extract, a buffer adjusted to a pH of from 4 to 8; and the surfactant poloxamer P407 in a con- centration of from 2.5 to 15 %w / v. The invention further relates to the use of the composition in the treatment of inflammatory and / or allergic conditions of the human body.

The invention discloses a sicca syndrome marker HMGB1 and application thereof, belongs to the field of biological medicine, and particularly relates to application of sicca syndrome marker high-mobility group protein B1 in diagnosis and treatment of sicca syndrome. The invention discloses that the expression of HMGB1 in salivary gland tissues of SS patients is obviously increased, the transcriptional level of key aquaporin AQP5 related to salivary secretion is obviously reduced, and the expression of HMGB1 is in negative correlation with the expression of AQP5. The invention also discloses application of the glycyrrhizin to inhibition of transcription or expression of the HMGB1 gene, and the glycyrrhizin is used as a sicca syndrome treatment preparation. The invention provides a potential new target for diagnosis and treatment of sicca syndrome, and has important clinical application value.

The present application relates to a polysaccharide modified drug phospholipid complex, wherein the drug phospholipid complex is prepared from a drug and a phospholipid, the drug includes oxymatrine and glycyrrhizin, and the polysaccharide modification is that the drug phospholipid complex is first modified by chitosan, and then the drug phospholipid complex coated with chitosan is modified by hyaluronic acid. The polysaccharide modified drug phospholipid complex of the present application can enhance the drug accumulation in tumor cells through synergistic effect and active targeting, and significantly improve the anti-tumor effect of the drug.

The present disclosure relates to an animal food composition comprising a source of glycyrrhizin for use for preventing and / or treating allergic inflammatory skin diseases wherein the said animal food composition is formulated to provide an animal a daily amount of glycyrrhizin in an amount of at least about 0.02 mg / kg of bodyweight.